Skip to main content
Premium Trial:

Request an Annual Quote

DNage To Participate in EU Study on Biomarkers of Aging

NEW YORK (GenomeWeb News) – DNage, a wholly owned subsidiary of Dutch biotech Pharming Group, said today that it will participate in a five-year European study that aims to identify biomarkers of human aging.
 
The project, called MARK-AGE, is an EU-wide consortium of 26 industry and academic partners funded under the Seventh Research Framework Program. The EU has awarded a total of around €12 million ($19 million) for the study. 
 
Germany’s University of Konstanz is leading the project, which will study about 4,000 volunteers between 35 and 74 years old. Subjects will be recruited from the general population, as well as from families with long-living parents and siblings that have already been recruited as part of the EU’s ongoing “Genetics of Healthy Aging” project.
 
DNage said that it plans to use its proprietary animal models to discover novel biomarkers of aging, and that it will recruit patients that suffer from Cockayne syndrome and other premature-aging syndromes to validate the identified biomarkers.
 
The consortium expects that biomarkers identified through the project could be used to predict the onset of age-related diseases and may be used as diagnostic markers or as therapeutic targets.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.